Merck & Co., Inc. vs REGENERON PHARMACEUTICALS, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Merck runs with 1.07 in debt for every dollar of equity and a current ratio of 1.3, while Regeneron carries almost no debt, 0.06, and holds 3.57 in current assets for each dollar of near-term claims. That cash-heavy footing shows up in what each keeps: Regeneron's 30% net margin doubles Merck's 14%, and its return on assets, near 11%, beats Merck's 7%. Merck answers on the equity line, about 19% to Regeneron's 14%, but its larger debt load is part of what lifts that figure. The market pays Merck near 33 times earnings and Regeneron under 15, and Merck adds a 2.8% dividend where Regeneron pays nothing and lets its free-cash yield, above 6%, speak instead. One leans on scale and a payout; the other keeps its options open with the balance sheet.
Comparison updated 2026-06-15.
| Metric | MRK | REGN |
|---|---|---|
| Price | $123.48 | $664.56 |
| Market cap | $305.2B | $71.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +6.2% | +8.8% |
| P/E | 34.8 | 16.2 |
| P/B | 6.65 | 2.28 |
| P/S | 4.64 | 4.80 |
| EV/EBITDA | 600.7 | 18.8 |
| Revenue growth | +2.9% | +6.5% |
| Operating margin | — | 17.8% |
| Net margin | 13.6% | 29.6% |
| Return on equity | 19.4% | 14.1% |
| Return on assets | 6.9% | 10.8% |
| Return on invested capital | — | 9.5% |
| FCF yield | 4.6% | 5.8% |
| Dividend yield | 2.7% | — |
| Debt / equity | 1.07 | 0.06 |
| Current ratio | 1.30 | 3.57 |
| Altman Z (solvency) | 7.31 | 6.60 |
| Piotroski F (quality) | 6 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.